India's GLP-1 Opportunity Lies Upstream

The next phase of the GLP-1 opportunity may not belong to branded drug manufacturers—it could belong to the companies powering the supply chain. As key patents expire and generic GLP-1 therapies gain traction, value is expected to shift upstream toward API manufacturers and CDMOs. India's established peptide capabilities, expanding manufacturing capacity, and growing export potential position it to play a pivotal role in the global GLP-1 value chain. This report examines the structural drivers, competitive landscape, regional adoption trends, and the listed Indian companies best positioned to benefit from this multi-year opportunity.